NCT02232581View on ClinicalTrials.gov

Study to Determine the Antiviral Activity and Safety of Alovudine in Nucleoside-experienced HIV-infected Subjects Experiencing Virologic Failure

PHASE2CompletedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

April 30, 2004

Primary Completion Date

December 31, 2004

Conditions
HIV Infections
Interventions
DRUG

Alovudine - low

DRUG

Alovudine - medium

DRUG

Alovudine - high

DRUG

Placebo

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY